US02043Q1076 - Common Stock

We assign a fundamental rating of **4** out of 10 to **ALNY**. **ALNY** was compared to 577 industry peers in the **Biotechnology** industry. **ALNY** scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. **ALNY** is valued quite expensive, but it does show an excellent growth.

In the past year **ALNY** has reported negative net income.

In the past 5 years **ALNY** always reported negative net income.

In the past 5 years **ALNY** reported 4 times negative operating cash flow.

With an excellent **Return On Assets** value of **-1.82%**, **ALNY** belongs to the best of the industry, outperforming **92.51%** of the companies in the same industry.

Looking at the **Return On Invested Capital**, with a value of **2.75%**, **ALNY** belongs to the top of the industry, outperforming **94.08%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.82% | ||

ROE | N/A | ||

ROIC | 2.75% |

ROA(3y)-22.27%

ROA(5y)-25.8%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

With an excellent **Operating Margin** value of **4.38%**, **ALNY** belongs to the best of the industry, outperforming **94.25%** of the companies in the same industry.

Looking at the **Gross Margin**, with a value of **87.00%**, **ALNY** belongs to the top of the industry, outperforming **90.77%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 4.38% | ||

PM (TTM) | N/A | ||

GM | 87% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.45%

GM growth 5Y-3.18%

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so **ALNY** is destroying value.

The debt/assets ratio for **ALNY** has been reduced compared to a year ago.

With a decent **Altman-Z score** value of **3.92**, **ALNY** is doing good in the industry, outperforming **77.18%** of the companies in the same industry.

With an excellent **Debt to FCF ratio** value of **3.21**, **ALNY** belongs to the best of the industry, outperforming **97.04%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | 3.21 | ||

Altman-Z | 3.92 |

ROIC/WACC0.26

WACC10.49%

A Current Ratio of **3.01** indicates that **ALNY** has no problem at all paying its short term obligations.

With a **Current ratio** value of **3.01**, **ALNY** is not doing good in the industry: **67.25%** of the companies in the same industry are doing better.

Looking at the **Quick ratio**, with a value of **2.93**, **ALNY** is doing worse than **66.38%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 3.01 | ||

Quick Ratio | 2.93 |

Looking at the last year, **ALNY** shows a very strong growth in **Revenue**. The Revenue has grown by **89.46%**.

EPS 1Y (TTM)92.48%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%94.12%

Revenue 1Y (TTM)89.46%

Revenue growth 3Y54.8%

Revenue growth 5Y89.46%

Sales Q2Q%107%

Based on estimates for the next years, **ALNY** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **40.96%** on average per year.

Based on estimates for the next years, **ALNY** will show a very strong growth in **Revenue**. The Revenue will grow by **21.28%** on average per year.

EPS Next Y-1.61%

EPS Next 2Y23.94%

EPS Next 3Y39.84%

EPS Next 5Y40.96%

Revenue Next Year2.74%

Revenue Next 2Y12.97%

Revenue Next 3Y19.09%

Revenue Next 5Y21.28%

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **ALNY**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Based on the **Enterprise Value to EBITDA** ratio, **ALNY** is valued cheaper than 93.21% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 106.9 | ||

EV/EBITDA | 195.09 |

A more expensive valuation may be justified as **ALNY**'s earnings are expected to grow with **39.84%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.94%

EPS Next 3Y39.84%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**ALNYLAM PHARMACEUTICALS INC**

NASDAQ:ALNY (8/9/2024, 7:00:00 PM)

After market: 269.52 0 (0%)**269.52**

**-0.94 (-0.35%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap34.09B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.82% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 4.38% | ||

PM (TTM) | N/A | ||

GM | 87% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.58

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 3.01 | ||

Quick Ratio | 2.93 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)92.48%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-1.61%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)89.46%

Revenue growth 3Y54.8%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y